The Role of “Physiologically Based Pharmacokinetic Model (PBPK)” New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment
Top Cited Papers
Open Access
- 16 February 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (4) , 3473
Abstract
Physiologically Based Pharmacokinetic (PBPK) models are mechanistic tools generally employed in the pharmaceutical industry and environmental health risk assessment. These models are recognized by regulatory authorities for predicting organ concentration–time profiles, pharmacokinetics and daily intake dose of xenobiotics. The extension of PBPK models to capture sensitive populations such as pediatric, geriatric, pregnant females, fetus, etc., and diseased populations such as those with renal impairment, liver cirrhosis, etc., is a must. However, the current modelling practices and existing models are not mature enough to confidently predict the risk in these populations. A multidisciplinary collaboration between clinicians, experimental and modeler scientist is vital to improve the physiology and calculation of biochemical parameters for integrating knowledge and refining existing PBPK models. Specific PBPK covering compartments such as cerebrospinal fluid and the hippocampus are required to gain mechanistic understanding about xenobiotic disposition in these sub-parts. The PBPK model assists in building quantitative adverse outcome pathways (qAOPs) for several endpoints such as developmental neurotoxicity (DNT), hepatotoxicity and cardiotoxicity. Machine learning algorithms can predict physicochemical parameters required to develop in silico models where experimental data are unavailable. Integrating machine learning with PBPK carries the potential to revolutionize the field of drug discovery and development and environmental risk. Overall, this review tried to summarize the recent developments in the in-silico models, building of qAOPs and use of machine learning for improving existing models, along with a regulatory perspective. This review can act as a guide for toxicologists who wish to build their careers in kinetic modeling.Keywords
All Related Versions
Funding Information
- European Commission (101057014)
This publication has 88 references indexed in Scilit:
- Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2013
- Reconstruction of Exposure tom-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo SimulationJournal of Toxicology, 2012
- Physiologically based pharmacokinetics (PBPK)Drug Metabolism Reviews, 2009
- In vitro measurements of metabolism for application in pharmacokinetic modelingPharmacology & Therapeutics, 2008
- Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterionsJournal of Pharmaceutical Sciences, 2006
- Volume of Distribution at Steady State for a Linear Pharmacokinetic System with Peripheral EliminationJournal of Pharmaceutical Sciences, 2004
- Protein binding predictions in infantsAAPS PharmSci, 2002
- Enterohepatic CirculationClinical Pharmacokinetics, 2002
- Physiological Parameter Values for Physiologically Based Pharmacokinetic ModelsToxicology and Industrial Health, 1997
- An algorithm for predicting tissue : Blood partition coefficients of organic chemicals fromn‐octanol: Water partition coefficient dataJournal of Toxicology and Environmental Health, 1995